Chemomab Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference

Rhea-AI Summary

Chemomab Therapeutics (Nasdaq: CMMB) has announced its participation in the virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11, 2025. CEO Dr. Adi Mor and senior management will deliver a corporate presentation at 8:00 am ET, which will be webcast live and available on the company's website for 90 days.

Chemomab is advancing CM-101, a first-in-class monoclonal antibody targeting CCL24, for fibro-inflammatory diseases. The company recently reported positive results from its Phase 2 SPRING trial in primary sclerosing cholangitis (PSC). Two key milestones are expected in early 2025: establishing an FDA registrational pathway for CM-101's Phase 3 pivotal trial and reporting data from the SPRING trial open label extension.

The company plans to initiate the PSC Phase 3 trial by year-end. CM-101 has received FDA and EMA Orphan Drug and FDA Fast Track designations for PSC treatment. Additionally, their CM-101 program for systemic sclerosis is Phase 2-ready with an open U.S. IND.

News Market Reaction – CMMB

+4.41%

1 alert

+4.41% News Effect

On the day this news was published, CMMB gained 4.41%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

TEL AVIV, Israel, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that CEO Dr. Adi Mor and other members of its senior management team will deliver a corporate presentation and participate in one-on-one investor meetings at the virtual Oppenheimer 35^th Annual Healthcare Life Sciences Conference on February 11, 2025. The Oppenheimer Conference presentation will be webcast live and will be available on the investor relations section of the Chemomab website for 90 days.

Oppenheimer 35th Annual Healthcare Life Sciences Conference
Date:	February 11, 2025
Time:	8:00 am ET
Venue:	Virtual
Format:	Webcast presentation
Webcast Link:	https://wsw.com/webcast/oppenheimer39/cmmb/2752408
Information:	opcoconferences@opco.com

About Chemomab Therapeutics Ltd.
Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a first-in-class dual activity monoclonal antibody that neutralizes CCL24 and has demonstrated disease-modifying potential. In clinical and preclinical studies, CM-101 has been shown to have a favorable safety profile and has been generally well-tolerated, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Chemomab has reported positive results from four clinical trials of CM-101 in patients. Based on recent positive data from its Phase 2 SPRING trial in primary sclerosing cholangitis (PSC), the company expects two milestones in early 2025 – achieving a clear FDA registrational pathway for the planned CM-101 Phase 3 pivotal trial and reporting data from the SPRING trial open label extension. Chemomab is targeting initiation of the PSC Phase 3 trial before the end of the year. CM-101 has received FDA and EMA Orphan Drug and FDA Fast Track designations for the treatment of PSC. Chemomab’s CM-101 program for the treatment of systemic sclerosis is Phase 2-ready with an open U.S. IND. For more information, visit: chemomab.com.

Contacts:

Media and Investors:
Barbara Lindheim
Consulting Vice President, Investor & Public Relations, Strategic Communications
Phone: +1 917-355-9234
barbara.lindheim@chemomab.com
IR@chemomab.com

FAQ

When will Chemomab (CMMB) present at the Oppenheimer Healthcare Conference 2025?

Chemomab will present at the Oppenheimer Healthcare Conference on February 11, 2025, at 8:00 am ET in a virtual format.

What are the key milestones expected for Chemomab's CM-101 drug in early 2025?

Chemomab expects to achieve a clear FDA registrational pathway for CM-101's Phase 3 pivotal trial and report data from the SPRING trial open label extension in early 2025.

What regulatory designations has CM-101 received for PSC treatment?

CM-101 has received FDA and EMA Orphan Drug designations and FDA Fast Track designation for the treatment of primary sclerosing cholangitis (PSC).

When does Chemomab (CMMB) plan to start the Phase 3 trial for CM-101 in PSC?

Chemomab plans to initiate the Phase 3 trial for CM-101 in PSC before the end of 2025.

What diseases is Chemomab's CM-101 being developed to treat?

CM-101 is being developed to treat fibro-inflammatory diseases, specifically primary sclerosing cholangitis (PSC) and systemic sclerosis.